134253-05-7

Upstream product

• 455917-34-7 Methane Sulfonic Acid-4-aminomethyl-1-benzyl-pyrrolidine-3-yl Ester 
• 780-15-4 1-benzyl-3-hydroxymethyl-4-hydroxypyrrolidine 
• 134253-02-4 Methanesulfonic acid (3S,4R)-4-aminomethyl-1-benzyl-pyrrolidin-3-yl ester 
• 134253-00-2 Methanesulfonic acid (3S,4S)-1-benzyl-4-methanesulfonyloxymethyl-pyrrolidin-3-yl ester 
• 134253-03-5 Methanesulfonic acid (3S,4R)-1-benzyl-4-[(2,2,2-trifluoro-acetylamino)-methyl]-pyrrolidin-3-yl ester 
• 134253-04-6 1-((1R,5S)-3-Benzyl-3,6-diaza-bicyclo[3.2.0]hept-6-yl)-2,2,2-trifluoro-ethanone 

Downstream Products

• 134253-06-8 7-((1R,5S)-3-Benzyl-3,6-diaza-bicyclo[3.2.0]hept-6-yl)-1-tert-butyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Modulators of chemokine receptor activity

Chemokine receptor antagonists, in particular, bicyclic diamine compounds of Formula (I) that act as antagonists of chemokine CCR2 and CCR3 receptors including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leucocyte accumulation are described herein.

Synthesis of a new bridged diamine 3,6-diazabicyclo [3.2.0] heptane: Applications to the synthesis of quinolone antibacterials

Diprotected 3,6-diazabicyclo [3.2.0] heptane has been prepared by an highly efficient process. Selective deprotection, followed by condensation with 7-halogenoquinolones led to the naphthyridones 10 and 13 and the quinolone 14.